Boundless Bio, Inc.
BOLDHealthcare|Biotechnology|US
$2.46
+0.05 (+2.07%)
Tangible Book / Share
$2.94
Cash / Share
$3.24
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06299761 Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications | Solid Tumor | P1 | Terminated | 19 | Open-label | BBI-825 |
| NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | P1 | Terminated | 85 | Open-label | BBI-355, Erlotinib, Futibatinib, BBI-825 |
| NCT07408089 Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | Breast Cancer, Metastatic Breast Cancer | P1 | Terminated | 8 | Open-label | BBI-940, Fulvestrant |